- Home
- EBC vs NAMS Comparison
EBC vs NAMS Comparison
Compare EBC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBC | NAMS |
|---|---|---|
| Founded | 1818 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.0B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | EBC | NAMS |
|---|---|---|
| Price | $18.83 | $35.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $21.67 | ★ $46.40 |
| AVG Volume (30 Days) | ★ 2.1M | 986.7K |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $627,584,000.00 | $35,243,000.00 |
| Revenue This Year | $28.16 | N/A |
| Revenue Next Year | $32.65 | N/A |
| P/E Ratio | $77.30 | ★ N/A |
| Revenue Growth | 3.01 | ★ 4.91 |
| 52 Week Low | $13.51 | $14.06 |
| 52 Week High | $20.19 | $42.00 |
Technical Indicators
Market Signals| Indicator | EBC | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 46.52 |
| Support Level | $18.62 | $32.85 |
| Resistance Level | $18.89 | $37.00 |
| Average True Range (ATR) | 0.47 | 1.52 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 36.05 | 54.17 |
Price Performance
Historical ComparisonAbout EBC Eastern Bankshares Inc.
Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment; Banking business which offers a range of banking lending, savings, and small business offerings, and its wealth management and trust operations.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.